Skip to main content
. 2018 Dec 6;16:343. doi: 10.1186/s12967-018-1717-y

Table 2.

Summary of the slopes of CD4+ T-cells recovery (cells/mm3/month) for each mtDNA haplogroup and the relationship between them in HIV-infected patients who started combined antiretroviral therapy

Mt DNA haplogroups Unadjusted analysis* Adjusted analysis**
No Yes p-value aAMR (95% CI) p-value
Clusters or major haplogroups
 HV 9.1 (5.5; 14) 10 (6.4; 14.7) 0.288 0.98 (0.86; 1.13) 0.839
 U 9.8 (6.2; 14.1) 9.1 (5.1; 13.9) 0.321 0.91 (0.77; 1.08) 0.300
 JT 9.8 (6.2; 14) 9.2 (5.6; 13.6) 0.765 1.12 (0.94; 1.33) 0.205
Haplogroups
 H 9.1 (5.6; 13.7) 10.2 (6.9; 14.1) 0.075 1.04 (0.91; 1.21) 0.544
 J 9.8 (6.2; 14) 8.8 (5.2; 12.2) 0.522 1.07 (0.86; 1.32) 0.537
 T 9.6 (6.1; 14) 9.7 (6.8; 14.2) 0.735 1.17 (0.90; 1.51) 0.225

HIV human immunodeficiency virus, aAMR adjusted arithmetic mean ratio, CI confidence interval

Statistical: * Values were expressed as median (cells/mm3/month) (percentile 25; percentile 75). p-values were calculated by Mann–Whitney tests. ** Values were expressed as adjusted arithmetic mean ratio (aAMR) and 95% of confidence interval (95% CI) of the slopes of CD4+ T-cells recovery (cells/mm3/month). p-values were calculated by Generalized Linear Models test with a normal distribution (log-link). These regressions were adjusted by the most important clinical and epidemiological characteristics (gender, age, length of HIV-infection, baseline CD4+ cells/mm3, HIV transmission route related to IDU, hepatitis C and hepatitis B coinfection, and type of cART regimen)